Targets RHOA-VAV1 signaling in AITL, and in a population of patients which responded to dasatinib 3 of 4 (75%) held a RHOA or VAV1 mutation. This evidence concerns the gene VAV1 and angioimmunoblastic T-cell lymphoma.